Stock Market Reviews

Read and share opinions on NXL (Nexalin Technology, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
  Nov 13, 2025
• Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
  Nov 5, 2025
• Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
  Oct 30, 2025
• Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
  Oct 21, 2025
• Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Oct 17, 2025
• Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
  Oct 13, 2025
• Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
  Oct 10, 2025
• Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
  Oct 8, 2025
• Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
  Sep 25, 2025
• Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
  Aug 25, 2025
• Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
  Aug 1, 2025
• Nexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  May 30, 2025
• Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
  May 28, 2025
• Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
  May 13, 2025
• Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
  May 6, 2025
• Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
  May 5, 2025
• Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
  May 1, 2025
• Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
  Apr 24, 2025